- Dana-Farber scientists report on a natural hormone that is increased by physical exercise and by exposure to cold improves blood sugar control, suppresses inflammation, and burns fat to mold leaner bodies in mice can be made in the laboratory and could have therapeutic potential for several diseases.
- Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.
Tags: BreastCancer, ProstateCancer
- Researchers find young adults who lack health care insurance are more likely to be diagnosed in advanced stages of cancer and have a higher risk of death.
Tags: Radiation, PopulationScience
- Dana-Farber researchers and colleagues report that men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting for the disease to become resistant to hormone-blockers.
- Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally.
Tags: OvarianCancer, TargetedTherapy
- Erica Mayer, MD, MPH, and colleagues are leading a pilot phase 2 clinical trial to test the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.
Tags: BreastCancer, TargetedTherapy
- New research shows patients with non-metastatic ovarian cancer live longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it.
- A new study shows about half of non-small cell lung cancer (NSCLC) patients whose tumors no longer responded to conventional targeted drugs had their tumors shrink after receiving a new, more precisely targeted agent.
Tags: EGFR, LungCancer
- According to new research, a technique for reading the genetic abnormalities in patient tumors with a simple blood test has passed a critical test of accuracy and reliability.
- F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.
Tags: Melanoma, Immunotherapy
Showing 21-30 of 522 items